

Invictus Therapeutics Ltd – Cornwalls Dispute

Sydney, New South Wales, 22 July 2026 – The directors of Invictus Therapeutics Ltd (**Invictus**) (formerly VGI Health Technology Limited (NSX:VTL) advise that the Company has been served with an Application to Wind Up the Company by Cornwalls (the **Application**).

The Board has instructed the Company's lawyers to negotiate a resolution to the matters leading up to the service of the Application and will update Shareholders accordingly.

This announcement was authorised for release by the Board of the Company.

For more information please contact:

Glenn Tong, CEO and Managing Director
Ph: +61 (0) 412 193 350

Catriona Glover, Company Secretary
Tel: +61 (0) 402 328 200

About Invictus Therapeutics Ltd

Invictus Therapeutics Ltd (formerly VGI Health Technology Limited (NSX:VTL)) is an Australian public listed biotechnology company developing and commercialising prescription medicines and novel dietary supplements based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Metabolic dysfunction-Associated Fatty Liver Disease (MAFLD), Metabolic dysfunction-Associated Steatohepatitis (MASH), pancreatic adenocarcinoma (pancreatic cancer), hyperlipidaemia, hypertension and diabetes. Invictus owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a clinical development program for prescription medicines and a product development program for evidence-based nutraceuticals.